# data[].attributes.headline
THE EFFECTIVENESS OF VORAXAZE SHOWN IN LONG-TERM RETROSPECTIVE STUDY

# data[].attributes.subject
THE EFFECTIVENESS OF VORAXAZE SHOWN IN LONG-TERM RETROSPECTIVE STUDY

# data[].attributes.body
Based in Chester County, PA, Kenneth Pugh guided pharmaceutical company BTG International, Inc., in a successful turnaround. In addition to his work with BTG International, Kenneth (Ken) Pugh served as the global franchise leader at Voraxaze from 2011 to 2013 and achieved numerous breakthroughs. His efforts resulted in Voraxaze being added to the NCCN Cancer Guidelines as the standard of care.

# data[].attributes.attachment_link.title
CMS grants new prospective reimbursement for Voraxaze®

# data[].attributes.attachment_link.description
WEST CONSHOHOCKEN, Pa., Sept. 5, 2012 /PRNewswire/ -- BTG International Inc., the specialist healthcare company, today announces that the Centers for Medicare...

# data[].attributes.headline
BTG Joins Global Liver Institute Partnership Network to Transform Care for Liver Cancer Patients — Global Liver Institute

# data[].attributes.subject
BTG Joins Global Liver Institute Partnership Network to Transform Care for Liver Cancer Patients — Global Liver Institute

# data[].attributes.attachment_link.readable_text
Washington, DC (June 9, 2016) -- The Global Liver Institute (GLI), the innovation and collaboration platform for the liver community worldwide, announced today that BTG, a global leader in interventional oncology, has joined GLI's Partnership Network as a founding member. BTG will provide expertise and support on key initiatives to help transform care for liver cancer patients.

GLI's portfolio of liver cancer initiatives includes the Reimagine Liver Cancer stakeholder workshop, the HCC360 Registry & Biorepository, and the Personalized Medicine in Liver Diseases meeting.

GLI established the Partnership Network in January 2016 to bring together like-minded organizations and individuals to fundamentally transform advocacy in the liver field. The Partnership Network addresses the need for initiatives that cross disciplines, sectors, and stakeholder groups to advance patient-centered research, education, and health system delivery solutions.

"We are delighted to welcome BTG to our Partnership Network. Their knowledge and experience in the complexities of liver cancer care will be an important contribution to the Partnership Network" stated Donna R. Cryer, JD, President, & CEO of the Global Liver Institute. "According to the most recent data, liver cancer is the second most deadly cancer worldwide and one of the few cancers that is rising in incidence."

BTG's interventional oncology portfolio is transforming the way cancer is being treated by discovering and developing differentiated therapeutic innovations for hard to treat primary and secondary liver cancers. The BTG interventional oncology portfolio offers the flexibility to treat patients through embolization and internal radiation, with minimally invasive treatments that go precisely where they are needed. BTG is also conducting research in these areas to extend the reach of science and technology over liver disease.

Ken Pugh, BTG Vice President, Commercial Development and Interventional Oncology Marketing, the Americas remarked, "We are excited to come on board as a founding member of the Global Liver Institute Partnership Network. BTG is committed to improving patient outcomes by delivering continued advancements in personalized, loco-regional cancer therapies. We believe passionately that interventional oncology has the power to improve human health and our partnership with the GLI will help to build connections across the liver community to transform cancer care."

GLI and BTG call for more public attention to liver cancer, mechanisms that promote earlier diagnosis, increased transparency and education on the dangers of cumulative risk factors for liver cancer, assistance for patients and families navigating the liver cancer care journey, and the need for increased participation in research.

The GLI board includes renowned liver cancer experts Lewis R. Roberts, MB, ChB, PhD of Mayo Clinic and Melanie Thomas, MS, MS at the Gibbs Cancer Center & Research Institute, the founder of CanLiv, the Hepatobiliary Cancers Foundation now part of GLI.

# data[].attributes.attachment_link.title
BTG Joins Global Liver Institute Partnership Network to Transform Care for Liver Cancer Patients

# data[].attributes.attachment_link.description
Washington, DC (June 9, 2016) -- The Global Liver Institute (GLI), the innovation and collaboration platform for the liver community worldwide, announced today that BTG, a global leader in interventional oncology, has joined GLI's Partnership Network as a founding member. BTG will provide expertise and support on key initiatives to help transform care for liver cancer patients.

# data[].attributes.headline
Voraxaze® (glucarpidase) Launched in the US | BTG plc | United States

# data[].attributes.subject
Voraxaze® (glucarpidase) Launched in the US | BTG plc | United States

# data[].attributes.attachment_link.readable_text
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze ® (glucarpidase) in the US. Voraxaze ® is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Voraxaze ® breaks down methotrexate into inactive metabolites which are then eliminated from the body by routes other than the kidney (primarily the liver). Voraxaze ® is the first and only drug available to reduce toxic plasma methotrexate levels.

High dose methotrexate chemotherapy is used to treat or prevent the recurrence of certain cancers, including osteosarcoma, and certain leukemias, and lymphomas. Some patients treated with high dose methotrexate develop impaired kidney function, which leads to the accumulation of toxic levels of methotrexate in the blood resulting in clinical manifestations of toxicity.

The most common related adverse events in clinical trials were paresthesia (a sensation of tingling or burning on the skin), flushing, nausea, vomiting, hypotension and headache.

Further information on the symptoms, diagnosis and treatment of methotrexate toxicity is available for US physicians in the US Healthcare Professional area of BTG's website, accessible through the link at the bottom of this press release.

BTG also announces that the company is partnering with ASD Healthcare, part of the AmerisourceBergen Corporation, to be the sole distributor for Voraxaze ® in the US. Starting today 30 April 2012, ASD Healthcare is accepting customer orders for Voraxaze ® at 1.855.7.VORAXAZE (1.855.786.7292) with on-call representatives to process orders 24-hours a day, 365 days a year.

Voraxaze ® was approved earlier this year by the FDA under priority review, a designation that is given to therapies that offer major advances in treatment or provide a treatment where there is no adequate alternative therapy.

Dosing

Voraxaze ® is to be administered as a single intravenous injection of 50 Units per kg.

Safety Information
Most common adverse reactions (incidence >1%) were paresthesias, flushing, nausea and/or vomiting, hypotension and headache.

Healthcare providers should note that:

Methotrexate concentrations within 48 hours following glucarpidase administration can only be reliably measured by a chromatographic method due to interference from metabolites [4-deoxy-4-amino-N¹⁰-methylpteroic acid (DAMPA)]. Measurement of methotrexate concentrations within 48 hours of glucarpidase administration using immunoassays can overestimate the methotrexate concentration.

Leucovorin should not be administered within 2 hours before or after a glucarpidase dose because leucovorin is a substrate for glucarpidase.

For further information please contact:

BTG
Ashley Tapp, Communications Manager
Tel: +44 (0)20 7575 1513
Mobile: +44 (0)7790 811554

# data[].attributes.attachment_link.title
Voraxaze® (glucarpidase) Launched in the US

# data[].attributes.attachment_link.description
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze® (glucarpidase) in the US. Voraxaze® is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired re

# data[].attributes.headline
BTG announces US Launch of radiopaque embolic bead, LC Bead Lumi - Interventional News

# data[].attributes.subject
BTG announces US Launch of radiopaque embolic bead, LC Bead Lumi - Interventional News

# data[].attributes.attachment_link.readable_text
BTG has announced the launch of LC Bead Lumi in the USA, the first commercially available radiopaque embolic bead for the embolization of hypervascular tumours and arteriovenous malformations. LC Bead Lumi is a next generation development of LC Bead.
The unique visibility of LC Bead Lumi during and after embolization supports the optimisation of patient treatment by enabling real-time visible confirmation of bead location during the procedure. This provides interventional radiologists more control, while at the same time facilitating discovery of regions of under-treatment, allowing precise evaluation of the completeness of tumour treatment and enhanced endpoint determination, with long-lasting radiopacity to support follow-up management.

"The launch of LC Bead Lumi has the potential to be a real game-changer in the field of embolization," said Raj Narayanan, associate professor of Clinical Radiology at the University of Miami, Miami, USA. "Not only does it provide doctors and patients with reassurance that the tumour has been treated in its entirety, but it allows interventional radiologists like me to refine treatment as we go, with the subsequent prospect of improved outcomes for patients."

LC Bead Lumi has been developed on the same technology platform and to the same high standard as LC Bead, building upon its market leading clinical performance, the release adds.

"With the launch of LC Bead Lumi, BTG is helping to ensure embolization technology achieves its full potential," commented Ken Pugh, BTG vice president, Commercial Development and Interventional Oncology Marketing, the Americas. "The potential benefits of LC Bead Lumi are significant - it represents a new level of control and offers the unique opportunity to individualise patient treatment in order to help doctors see more and treat smarter, while at the same time providing reassurance to patients that the treatment is getting to where it needs to be. At BTG, we are passionate about the potential of LC Bead Lumi and the power of interventional oncology to improve human health."

The launch represents the first market commercialisation for LC Bead Lumi, with regulatory clearances and launches planned for additional radiopaque bead products worldwide.

Visit BTG at the SIR annual scientific meeting 2016 in Vancouver, Canada, and learn more about LC Bead Lumi during the symposium"As We See it: LC Bead Lumi Clinical Experience From Early Users" scheduled for Tuesday 5 April, 1200 noon, Room 121/122.

(Visited 103 times, 1 visits today)

# data[].attributes.attachment_link.title
BTG announces US Launch of radiopaque embolic bead, LC Bead Lumi - Interventional News

# data[].attributes.attachment_link.description
BTG has announced the launch of LC Bead Lumi in the USA, the first commercially available radiopaque embolic bead for the embolization of hypervascular tumours and arteriovenous malformations. LC Bead Lumi is a next generation development of LC Bead.

# data[].attributes.headline
Digital Marketing Trends for 2018: The Experts Weigh In - IMA

# data[].attributes.subject
Digital Marketing Trends for 2018: The Experts Weigh In - IMA

# data[].attributes.attachment_link.readable_text
For the last several years, marketers have been pushing more and more of their chips against Digital (often stealing from traditional marketing budgets to do so). Finally, in 2016, digital advertising spend surpassed TV for the first time ... and, by the time 2017 ends, that gap will have widened by roughly $10 billion.

But it's not just about budgeting for digital, or merely "doing" digital; it's about strategically executing digital marketing efficiently and effectively, and rising to the demands and expectations of the modern marketplace.

With 2018 just a few months away, it's time to review the lessons learned this year and start planning for next. We interviewed marketing experts - across a wide range of industries - to get their two-cents on the most critical digital marketing trends in 2018. Here's what they had to say ...

How do you see digital marketing evolving in 2018?

"Digital marketing will evolve in several areas such as video marketing, social networking, content marketing, content personalization, and identifying and cultivating brand ambassadors."

"2018 will be remembered as the year that established content marketing strategies died and were reborn into a different animal. The glut of content online has become nearly overwhelming, as has the lack of original, compelling content. Marketers must comply and reconsider their content strategy by moving from a volume play to a quality play, driven by creating content around topics their company is credible speaking to."

"Live video will continue its dominance. In fact, at an average of just 3 seconds per view, Facebook is generating over 3,000 years' worth of watch time each day! In 2018, this trend will continue sprouting as more brands decide to dive in."

"[In life sciences], digital marketing can improve through the collection, synthesis, and communication of pharmaco-economic and/or real-world data to the extent allowable by laws and regulations."

"While there's lots of talk about machine learning - like there was about big data in previous years - B2B digital marketers will be challenged to apply emerging technologies in 2018 and will, instead, focus on increasing their adoption of more mature tools such as marketing automation and implementing tools that will help connect the dots from lead generation to closed sales."

"Broadly speaking, I don't see us on the verge of a material transformation in 2018. Digital marketing isn't a one size fits all box, so chasing the latest and greatest isn't always appropriate. Understanding what the customer values and how that meshes with business objectives will still be a pillar of a good digital strategy. That said, customer centricity will become an even bigger topic in 2018 and marketers who place emphasis on outside-in strategies will outperform those who don't."

What do you think is driving these changes, and why?

"Mainly competition and customer expectations. B2C expectations are now B2B expectations - so it needs to be digital, it needs to feel customized, and you need to get it right the first time."

"With the explosion of data throughout the marketing stack, marketers are focused on how to use that insight to make meaningful, informed decisions to create more targeted campaigns that can be measured and refined. Previously there was a broader approach of 'if we put it out there, they will consume it,' and the approach will become more refined to direct relevant content to the buyer when and where they need it."

"For attribution, there is so much money being spent on social and emerging digital channels, but what is it actually bringing in? We know we need to be there, but we need to be thoughtful about where and how much. We can't know that without proper metrics and attribution. In this environment, we all need to be smarter with our marketing dollar."

"I think the persona of the guy or gal at home and how they choose to consume products is now applied to their business persona. They want immediate access to the top-rated products and the ability to fully understand their benefits, competing products and reviews to make sound business decisions - and perhaps be able to reduce the pain and amount of time associated with the procurement process."

"Digital marketers have become more skilled at utilizing marketing automation. They are now ready to take the next step to fully exploit its capabilities. As they do so, they will begin to realize that marketing automation may not be enough to demonstrate ROI and their contribution to the bottom line."

"Words, images, maps, status updates, comments, emojis, numbers, infographics, sponsored ads ... Zzzz. This is a normal social news feed you scroll through with rote tedium every day, eyes glazing over the cluttered landscape until an auto-play video catches your attention and you stop dead in your tracks. No matter what it is - a quick-hit recipe, the trailer to the 'Blade Runner 2049' film, a new wacky flavor of Lay's potato chips - you stop scrolling and watch, even if it's for just a moment. And that's the power of this medium; the ability to stand out from the crowd.

How will these changes affect your day-to-day operations - and/or your marketing budget?

"Our team will invest additional time, energy and budget into our video content strategy in 2018. We will utilize our brand ambassadors for content development and delivery across social media platforms that reach our target audience."
Fran Howell, Director Digital Media, Johnson & Johnson Diabetes Institute
"Big shifts away from physical events. Big shifts to digital strategies. Bigger focus on content than ever before."

"Quality content requires quality personnel. I suspect we'll see marketing budgets focus more attention in two areas: editorial/communications professionals and marketing analytics experts (marketing analytics guiding the editorial/communications professionals' writing topics)."

"Nirvana would mean that operations become more efficient. We shift budgetary dollars to produce high-quality assets that serve specific points along the buyer's journey. We improve websites that offer immediate service, all mobile-friendly, and we increase our social footprint to join in and encourage conversations."

"There will be a need to reallocate spending from other (perhaps more traditional) areas of marketing in order to free up additional spending in digital marketing. Also, budget for pilots must be secured to experiment and evaluate new digital marketing solutions."

"At SAP, we partner with some of the most amazing sports leagues, teams, and players around the world. Live-streaming allows us to piggy-back off of these events, by creating digital opportunities specifically targeted at our audience. An example occurred at the World Cup of Hockey last year when we were able to stream to the public what would've previously been a private, fireside chat between SAP CEO, Bill McDermott and NHL Commissioner, Gary Bettman. The results were amazing and we positioned ourselves as thought leaders."

How difficult will it be to adjust to these changes?

"It's extremely difficult, particularly when sales is not in sync with the necessity of the change. This forces a stronger alignment between marketing and sales than ever before."

"Operationally, it should be an easy transition. Bureaucratically, it may be a tough sell to senior leadership who generally devalue any function for which a bottom-line ROI cannot easily be measured."

"It will be difficult. For example, there's no silver bullet of attribution, and aligning data sets can be challenging. Brand safety will be easier as long as the publisher can implement 3rd party tags."

"Data analysis is a skill set that will become part of the core strengths of all marketers."
Director of Marketing, Genex Services

"If you've never done video before, there will be an adjustment period but it shouldn't be too difficult. If you have a good script and a willing, flexible staff, you're closer to producing a solid video than you might realize."

"I think it will be difficult, mostly from an organizational perspective as multiple functions including marketing, communications and IT will need to work together. Establishing an organizational commitment to the strategy and how success will be measured is an important first step. There is also a potential talent gap. Employees with more of a t-shaped skill set will be able to contribute in a more meaningful way than those who go deep in one area."

If your prediction is right, what new goals/successes would you pursue?

"Accurately measuring marketing's contribution to the business, and creating plans using quantitative analysis in addition to qualitative data."

"We'd likely create a brand safety metric to show that we are alongside content that aligns with our brand. For attribution, it's to show that while people may experience 'banner blindness' or skip online videos, these still contribute to sales. No one questions a billboard, though no one can quantify precisely how it works."

"I mentioned that the average video is viewed for merely 3 seconds. A successful live-stream needs to hook the viewer instantly. And as new viewers are joining every few seconds, the content needs be engaging throughout the duration, which by the way, should remain short in length. However, when done correctly, we have the opportunity to create our own narrative to truly showcase how SAP software is literally changing the game, in ways that were never quite possible before."

"You must relate to your customers and prospects wherever they are in the sales cycle, and that means providing compelling, digestible content and multiple means to engage. We also should remember that our messaging needs to be about them, not about us. While credibility is important, we have to explain how we can help them, not just tout our accomplishments and awards."

"We've been on board with video for over a decade now, but the pursuit of live stream video is what we're focused on for 2018. 'What networks should we be on?', 'How often?' and 'In what capacity?' are all questions we're pondering now for our social media strategy going forward, with the goal being brand impact."

"At the most basic level, I'd want to see that customer acquisition costs have gone down and that leads are more sales ready than before. Beyond that I'd look to establish digital as a bigger part of competitive differentiation by measuring changes in domain authority, churn among digitized customers and improvements in customer outcomes tied to digital."

# # #

# data[].attributes.attachment_link.title
Digital Marketing Trends for 2018: The Experts Weigh In - IMA

# data[].attributes.attachment_link.description
For the last several years, marketers have been pushing more and more of their chips against Digital (often stealing from traditional marketing budgets to do so). Finally, in 2016, digital advertising spend surpassed TV for the first time ... and, by the time 2017 ends, that gap will have widened by roughly $10 billion.